Reasons for discontinuation vary by psoriasis treatment

August 10, 2012
Reasons for discontinuation vary by psoriasis treatment
The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

(HealthDay) -- The reasons for discontinuation of commonly used treatments for psoriasis vary by treatment, according to a study published online July 30 in the Journal of the American Academy of Dermatology.

Howa Yeung, from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues conducted interviews of 1,095 with moderate-to-severe plaque psoriasis to assess 11 reasons for treatment discontinuation for all past treatments (2,231 total).

The authors found that the median treatment duration ranged from 6.0 to 20.5 months (P < 0.001). For each treatment there was a significantly different frequency of each reason cited for discontinuation. A loss of efficacy was more likely to be cited by patients who received etanercept (odds ratio [OR], 5.19) and adalimumab (OR, 2.10) than by those who received methotrexate. Side effects were less likely to be cited by patients who received etanercept (OR, 0.34), adalimumab (OR, 0.48), or ultraviolet B phototherapy (OR, 0.21) than by those who received methotrexate, and were more likely to be cited by those who received acitretin (OR, 1.56). Inability to afford treatment was more likely to be cited by patients who underwent ultraviolet B phototherapy (OR, 7.03).

"A broad range of clinically relevant, patient-oriented reasons may explain why patients discontinue treatments," the authors write. "These results may inform the development of and evidence-based strategies to improve treatment satisfaction and to maintain successful long-term control."

Several authors disclosed financial ties to the .

Explore further: UVB preferred for treatment of moderate to severe psoriasis

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

UVB preferred for treatment of moderate to severe psoriasis

February 24, 2012
(HealthDay) -- Ultraviolet B (UVB) is preferred by dermatologists for first-line treatment of moderate to severe psoriasis in both healthy male and female patients, according to a study published in the March issue of the ...

Study compares effectiveness of psoriasis treatments

April 20, 2012
(HealthDay) -- The effectiveness of therapies for psoriasis is variable, and may be lower in real-world settings than in trial settings, according to a study published in the April issue of the Archives of Dermatology.

Short/long-term analyses deem etanercept safe for psoriasis

July 29, 2012
(HealthDay) -- Etanercept treatment is well tolerated for psoriasis, with no indication of dose-related or cumulative toxicity in short- or long-term analyses, according to a study published in the August issue of the Journal ...

Newer, more expensive psoriasis drugs only slightly more effective than older therapies under real world conditions

April 30, 2012
More expensive biologic treatments for psoriasis were only marginally more effective than standard treatments, according to a new study led by researchers in the Perelman School of Medicine at the University of Pennsylvania. ...

Many psoriasis patients undertreated for CV risk factors

June 22, 2012
(HealthDay) -- A large proportion of patients with moderate-to-severe plaque psoriasis are underdiagnosed and undertreated for cardiovascular (CV) risk factors, according to a study published in the July issue of the Journal ...

Treating psoriasis to prevent heart attacks and strokes

March 16, 2012
A clinical study co-led by the Montreal Heart Institute and Innovaderm Research Inc., which was presented today at the annual meeting of the American Academy of Dermatology, shows that a new treatment for psoriasis could ...

Recommended for you

New study offers insights on genetic indicators of COPD risk

January 16, 2018
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who have low, but stable, lung function early in life, and those who are particularly at risk ...

Previous influenza virus exposures enhance susceptibility in another influenza pandemic

January 16, 2018
While past exposure to influenza A viruses often builds immunity to similar, and sometimes different, strains of the virus, Canadian researchers are calling for more attention to exceptions to that rule.

Don't hold your nose and close your mouth when you sneeze, doctors warn

January 15, 2018
Pinching your nose while clamping your mouth shut to contain a forceful sneeze isn't a good idea, warn doctors in the journal BMJ Case Reports.

New antifungal provides hope in fight against superbugs

January 12, 2018
Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant ...

Dengue takes low and slow approach to replication

January 11, 2018
A new study reveals how dengue virus manages to reproduce itself in an infected person without triggering the body's normal defenses. Duke researchers report that dengue pulls off this hoax by co-opting a specialized structure ...

Different strains of same bacteria trigger widely varying immune responses

January 11, 2018
Genetic differences between different strains of the same pathogenic bacterial species appear to result in widely varying immune system responses, according to new research published in PLOS Pathogens.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

xgrassboy99
not rated yet Aug 11, 2012
I know it is Goofy. But, try Essential Oil.Melaleuca from doTerra is one of your best bets. It is really good at stopping the itching.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.